{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:37:41Z","timestamp":1783953461721,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"DFG","award":["TI 323\/4-1"],"award-info":[{"award-number":["TI 323\/4-1"]}]}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jcv.2017.04.008","type":"journal-article","created":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T12:46:12Z","timestamp":1491828372000},"page":"42-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A genotype independent, full-genome reverse-transcription protocol for HCV genotyping and resistance testing"],"prefix":"10.1016","volume":"91","author":[{"given":"Andreas","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Camdereli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Timm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2017.04.008_bib0005","doi-asserted-by":"crossref","DOI":"10.1111\/liv.13327","article-title":"Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies","author":"Di Maio","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.jcv.2017.04.008_bib0010","doi-asserted-by":"crossref","first-page":"e0153754","DOI":"10.1371\/journal.pone.0153754","article-title":"Using NS5B sequencing for hepatitis C virus genotyping reveals discordances with commercial platforms","volume":"11","author":"Chueca","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jcv.2017.04.008_bib0015","doi-asserted-by":"crossref","first-page":"e8209","DOI":"10.1371\/journal.pone.0008209","article-title":"Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice","volume":"4","author":"Chevaliez","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jcv.2017.04.008_bib0020","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1128\/JCM.00586-13","article-title":"Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0","volume":"51","author":"Larrat","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2017.04.008_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2015.10.010","article-title":"Diagnosis of hepatitis C virus genotype 2k\/1b needs NS5B sequencing","volume":"41","author":"De Keukeleire","year":"2015","journal-title":"Int. J. Infect. Dis.: IJID"},{"key":"10.1016\/j.jcv.2017.04.008_bib0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcv.2016.05.010","article-title":"New findings in HCV genotype distribution in selected West European, Russian and Israeli regions","volume":"81","author":"Kartashev","year":"2016","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2017.04.008_bib0035","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcv.2017.04.008_bib0040","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2017.04.008_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2017.04.008_bib0050","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/S0168-8278(15)30012-X","article-title":"Retreatment of patients who failed 8 or 12 weeks of ledipasvir\/sofosbuvir-based regimens with ledipasvir\/sofosbuvir for 24 weeks","volume":"62","author":"Lawitz","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2017.04.008_bib0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jcv.2015.07.008","article-title":"Natural prevalence of resistance-associated variants in hepatitis C virus NS5A in genotype 3a-infected people who inject drugs in Germany","volume":"70","author":"Walker","year":"2015","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2017.04.008_bib0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2017.04.008_bib0065","series-title":"Prescribing Information Zepatier","author":"US Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.jcv.2017.04.008_bib0070","series-title":"Prescribing Information Daklinza","author":"US Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.jcv.2017.04.008_bib0075","doi-asserted-by":"crossref","first-page":"e0155869","DOI":"10.1371\/journal.pone.0155869","article-title":"Geno2pheno[HCV] \u2013 a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents","volume":"11","author":"Kalaghatgi","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jcv.2017.04.008_bib0080","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jmv.21631","article-title":"Hepatitis C virus recombinants are rare even among intravenous drug users","volume":"82","author":"Viazov","year":"2010","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jcv.2017.04.008_bib0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0166-0934(94)90091-4","article-title":"Typing of hepatitis C virus isolates by DNA enzyme immunoassay","volume":"48","author":"Viazov","year":"1994","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2017.04.008_bib0090","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/JVI.05603-11","article-title":"Escape from a dominant HLA-B*15-restricted CD8+ T cell response against hepatitis C virus requires compensatory mutations outside the epitope","volume":"86","author":"Ruhl","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.jcv.2017.04.008_bib0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1743-422X-10-53","article-title":"Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples","volume":"10","author":"Zhang","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.jcv.2017.04.008_bib0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1128\/JVI.01993-15","article-title":"Distinct escape pathway by hepatitis C virus genotype 1a from a dominant CD8+ T cell response by selection of altered epitope processing","volume":"90","author":"Walker","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.jcv.2017.04.008_bib0105","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbrc.2006.06.039","article-title":"Efficient amplification and cloning of near full-length hepatitis C virus genome from clinical samples","volume":"346","author":"Fan","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jcv.2017.04.008_bib0110","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2144\/000112153","article-title":"Reverse transcription using random pentadecamer primers increases yield and quality of resulting cDNA","volume":"40","author":"Stangegaard","year":"2006","journal-title":"Biotechniques"},{"key":"10.1016\/j.jcv.2017.04.008_bib0115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jviromet.2012.06.011","article-title":"Genotyping and resistance profile of hepatitis C (HCV) genotypes 1\u20136 by sequencing the NS3 protease region using a single optimized sensitive method","volume":"185","author":"Besse","year":"2012","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2017.04.008_bib0120","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3109\/23744235.2015.1028097","article-title":"Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden","volume":"47","author":"Lindstrom","year":"2015","journal-title":"Infect. Dis."},{"key":"10.1016\/j.jcv.2017.04.008_bib0125","doi-asserted-by":"crossref","first-page":"e86413","DOI":"10.1371\/journal.pone.0086413","article-title":"HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in Sao Paulo, Brazil","volume":"9","author":"Nishiya","year":"2014","journal-title":"PLOS ONE"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138665321730118X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138665321730118X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T16:54:29Z","timestamp":1535907269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138665321730118X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":25,"alternative-id":["S138665321730118X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2017.04.008","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A genotype independent, full-genome reverse-transcription protocol for HCV genotyping and resistance testing","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2017.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}